Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesFinished GoodsInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShares OutstandingShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Karyopharm Therapeutics (KPTI) Other Non-Current Liabilities (2019 - 2025)

Karyopharm Therapeutics' Other Non-Current Liabilities history spans 8 years, with the latest figure at $72.3 million for Q4 2025.

  • For Q4 2025, Other Non-Current Liabilities fell 1.58% year-over-year to $72.3 million; the TTM value through Dec 2025 reached $72.3 million, down 1.58%, while the annual FY2025 figure was $72.3 million, 1.58% down from the prior year.
  • Other Non-Current Liabilities reached $72.3 million in Q4 2025 per KPTI's latest filing, up from $14.1 million in the prior quarter.
  • In the past five years, Other Non-Current Liabilities ranged from a high of $133.0 million in Q4 2021 to a low of $978000.0 in Q4 2023.
  • Average Other Non-Current Liabilities over 5 years is $79.8 million, with a median of $73.5 million recorded in 2024.
  • Peak YoY movement for Other Non-Current Liabilities: tumbled 99.26% in 2023, then soared 7415.24% in 2024.
  • A 5-year view of Other Non-Current Liabilities shows it stood at $133.0 million in 2021, then dropped by 0.21% to $132.7 million in 2022, then crashed by 99.26% to $978000.0 in 2023, then skyrocketed by 7415.24% to $73.5 million in 2024, then fell by 1.58% to $72.3 million in 2025.
  • Per Business Quant, the three most recent readings for KPTI's Other Non-Current Liabilities are $72.3 million (Q4 2025), $14.1 million (Q3 2025), and $73.5 million (Q2 2025).